David Ohlssen
Overview
Explore the profile of David Ohlssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sechidis K, Sun S, Chen Y, Lu J, Zhang C, Baillie M, et al.
Pharm Stat
. 2024 Dec;
24(2):e2463.
PMID: 39726118
This article proposes a Workflow for Assessing Treatment effeCt Heterogeneity (WATCH) in clinical drug development targeted at clinical trial sponsors. WATCH is designed to address the challenges of investigating treatment...
2.
Falck F, Zhu X, Ghalebikesabi S, Kormaksson M, Vandemeulebroecke M, Zhang C, et al.
J Biomed Inform
. 2024 Apr;
154:104641.
PMID: 38642627
Objective: Clinical trials involve the collection of a wealth of data, comprising multiple diverse measurements performed at baseline and follow-up visits over the course of a trial. The most common...
3.
Zimmermann M, Baillie M, Kormaksson M, Ohlssen D, Sechidis K
Clin Pharmacol Ther
. 2024 Feb;
115(4):774-785.
PMID: 38419357
Clinical trials are primarily conducted to estimate causal effects, but the data collected can also be invaluable for additional research, such as identifying prognostic measures of disease or biomarkers that...
4.
Bornkamp B, Zaoli S, Azzarito M, Martin R, Muller C, Moloney C, et al.
Pharm Stat
. 2024 Feb;
23(4):495-510.
PMID: 38326967
We present the motivation, experience, and learnings from a data challenge conducted at a large pharmaceutical corporation on the topic of subgroup identification. The data challenge aimed at exploring approaches...
5.
Coroller T, Sahiner B, Amatya A, Gossmann A, Karagiannis K, Moloney C, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(4):745-757.
PMID: 37965805
In 2020, Novartis Pharmaceuticals Corporation and the U.S. Food and Drug Administration (FDA) started a 4-year scientific collaboration to approach complex new data modalities and advanced analytics. The scientific question...
6.
Sun H, Plawinski J, Subramaniam S, Jamaludin A, Kadir T, Readie A, et al.
PLoS One
. 2023 Jul;
18(7):e0280316.
PMID: 37410795
Clinical data sharing can facilitate data-driven scientific research, allowing a broader range of questions to be addressed and thereby leading to greater understanding and innovation. However, sharing biomedical data can...
7.
Sun S, Sechidis K, Chen Y, Lu J, Ma C, Mirshani A, et al.
Biom J
. 2022 Nov;
66(1):e2100337.
PMID: 36437036
The identification and estimation of heterogeneous treatment effects in biomedical clinical trials are challenging, because trials are typically planned to assess the treatment effect in the overall trial population. Nevertheless,...
8.
Sechidis K, Kormaksson M, Ohlssen D
Stat Med
. 2021 Jul;
40(25):5453-5473.
PMID: 34328655
One of the key challenges of personalized medicine is to identify which patients will respond positively to a given treatment. The area of subgroup identification focuses on this challenge, that...
9.
Kormaksson M, Kelly L, Zhu X, Haemmerle S, Pricop L, Ohlssen D
Stat Med
. 2021 Apr;
40(14):3313-3328.
PMID: 33899260
Knockoffs provide a general framework for controlling the false discovery rate when performing variable selection. Much of the Knockoffs literature focuses on theoretical challenges and we recognize a need for...
10.
Bornkamp B, Ohlssen D, Magnusson B, Schmidli H
Pharm Stat
. 2016 Dec;
16(2):133-142.
PMID: 27935199
In many clinical trials, biological, pharmacological, or clinical information is used to define candidate subgroups of patients that might have a differential treatment effect. Once the trial results are available,...